Mediators of Inflammation, Prognostic Markers and Genetic Polymorphisms in Patients With Sepsis

Universitätsmedizin Mannheim

Status: Completed

Conditions: Sepsis

Treatments: Procedure: vein puncture

Study type: Interventional

Funder types: Other

Identifiers

NCT00222222

Nr.0244.4_1

0244.4

Details and patient eligibility

About

Aims of the study were to find vascular markers of inflammation and endothelial damage during the course of severe sepsis in septic patients and the effects of treatment with anti-inflammatory medication (such as Drotregocin alfa (activated)). Another aim is to find new markers and gene polymorphisms for prognosis and mortality of patients with severe sepsis. The hypothesis is that higher plasma concentrations of certain markers in septic patients are associated with a higher mortality rate.

Full description

During the past years many investigators have focused on the immunological changes in sepsis disease, and great attention has been paid to the development of practicable means of immunomonitoring. Human activated protein C (Drotrecogin alfa (activated)), an important coagulation inhibitor plays a major role in regulating microvascular coagulation, inflammation and immunology. Little is known about prognostic vascular biomarkers during the time course of patients with severe sepsis.

Enrollment: 105 patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• SIRS-Criteria
• Proven Infection
• One sepsis-induced organ-failure
• Adults <18 years old

Exclusion criteria

• Anemia
• Pregnancy
• Blood donor in the last 3 month

Trial design

Primary purpose: Diagnostic

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)